NG-25
|
|
|
- CAS番号.
- 1315355-93-1
- 化学名:
- 别名:
- 英語名:
- NG-25
- 英語别名:
- NG25;3-((1H-Pyrrolo[2,3-b]pyridin-4-yl)oxy)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide;NG-25;NG 25; NG-25;HG-7-92-01
(NG 25);NG-25 ISO 9001：2015 REACH;NG25,MAP kinase kinase kinase, MEKK, MAPKKK,NG 25,NG-25,MAP4K,inhibit,Inhibitor,MAP3K,MAPK Kinase Kinase Kinase;N-[4-[(4-Ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)benzamide;N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)benzamide;Benzamide, N-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-
- CBNumber:
- CB22645146
- 化学式:
- C29H30F3N5O2
- 分子量:
- 537.58
- MOL File:
- 1315355-93-1.mol
- MSDS File:
- SDS
|
NG-25 物理性質
- 比重(密度) :
- 1.313±0.06 g/cm3(Predicted)
- 貯蔵温度 :
- 2-8°C
- 溶解性:
- Soluble in DMSO
- 外見 :
- 粉
- 酸解離定数(Pka):
- 12.91±0.70(Predicted)
- 色:
- 白からベージュ
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| RIDADR |
UN 2811 6.1 / PGIII |
|
|
| 絵表示（GHS） |
|
| 注意喚起語 |
危険 |
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H301 |
飲み込むと有毒 |
急性毒性、経口 |
3 |
危険 |
|
P264, P270, P301+P310, P321, P330,P405, P501 |
| H413 |
長期的影響により水生生物に有害のおそれ |
水生環境有害性、慢性毒性 |
4 |
|
|
|
|
| 注意書き |
|
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TOC5429 |
NG 25 |
1315355-93-1 |
5mg |
￥114000 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
SML1332 |
≥98% (HPLC)
NG25 trihydrochloride ≥98% (HPLC) |
1315355-93-1 |
5mg |
￥33700 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
SML1332 |
≥98% (HPLC)
NG25 trihydrochloride ≥98% (HPLC) |
1315355-93-1 |
25mg |
￥109000 |
2024-03-01 |
購入 |
NG-25 化学特性,用途語,生産方法
使用
NG 25 inhibits TGF-beta-activated kinase 1 (TAK1). It also inhibits LYN, mitogen-activated protein kinase (MAP4K2) and Abl kinase activity.
Biochem/physiol Actions
NG25 is potent multiple kinase inhibitor belonging to type II kinase inhibitors class that binds to kinase ATP binding pocket at not ready to catalyze conformation. NG25 is used as a potent dual inhibitor of TAK1 (TGFβ-Activated Kinase 1, MAP3K7) and MAP4K2 (Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2; GCK) kinases. NG25 inhibits the activation of IKKa/IKKb and prevents the secretion of type 1 IFNs by TLR2 and TLR9 agonist.
NG-25 上流と下流の製品情報
原材料
準備製品
NG-25 生産企業
Global( 71)Suppliers
1315355-93-1()キーワード:
- 1315355-93-1
- N-[4-[(4-Ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)benzamide
- 3-((1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3v-(trifluoromethyl)phenyl)-4-methylbenzamide
- NG-25
- HG-7-92-01
(NG 25)
- N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)benzamide
- NG 25; NG-25
- Benzamide, N-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-
- NG-25 ISO 9001：2015 REACH
- NG25
- 3-((1H-Pyrrolo[2,3-b]pyridin-4-yl)oxy)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide
- NG25,MAP kinase kinase kinase, MEKK, MAPKKK,NG 25,NG-25,MAP4K,inhibit,Inhibitor,MAP3K,MAPK Kinase Kinase Kinase